Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsUnitedHealthcare Radicava ORS Prior Auth | OpenPay…
    Ask Trek AI about this page
    CurrentUnitedHealthcarePolicy N/A

    Radicava ORS (edaravone) Coverage Criteria

    Customize your policy alerts

    Sign up for all UnitedHealthcare policy alerts

    Know when UnitedHealthcare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and reauthorization for Radicava ORS used to treat amyotrophic lateral sclerosis (ALS) under UnitedHealthcare pharmacy benefits.

    Policy Summary
    PayerUnitedHealthcare
    PolicyRadicava ORS (edaravone) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionFor reauthorization, document a positive clinical response to Radicava ORS therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsInitial authorization duration
    12 monthsReauthorization duration
    1Covered indication

    Coverage Criteria

    Initial Authorization

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Covered when the following criterion is met:

    Initial authorization criterion: Diagnosis of amyotrophic lateral sclerosis (ALS)

    Authorization will be issued for 12 months.

    Reauthorization

    Covered when the following criterion is met:

    Reauthorization criterion: Documentation of positive clinical response to Radicava ORS therapy

    Authorization will be issued for 12 months.

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Authorization Required for ALS

    Submit an initial authorization request for Radicava ORS when the member has a diagnosis of amyotrophic lateral sclerosis (ALS). If approved, authorization is issued for 12 months.

    • Diagnosis required: Amyotrophic lateral sclerosis (ALS)
    • Authorization duration: 12 months
    Documentation Required

    Document Positive Clinical Response

    For reauthorization, document that the member has demonstrated a positive clinical response to Radicava ORS therapy. If approved, reauthorization is issued for 12 months.

    • Reauthorization documentation: Positive clinical response to Radicava ORS therapy
    • Authorization duration: 12 months
    • State mandates may apply. Federal regulatory requirements, the member-specific benefit plan, and other policies or utilization management programs may also affect coverage criteria.

    Therapy Overview

    Radicava ORS (edaravone) is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

    Initial Therapy

    Initial Authorization

    Initial authorization will be approved when the following criterion is met:

    Initial criterion: Diagnosis of amyotrophic lateral sclerosis (ALS)

    Authorization will be issued for 12 months.

    Reauthorization

    Reauthorization

    Reauthorization will be approved when the following criterion is met:

    Continuation criterion: Documentation of positive clinical response to Radicava ORS therapy

    Authorization will be issued for 12 months.

    Policy Summary
    PayerUnitedHealthcare
    PolicyRadicava ORS (edaravone) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionFor reauthorization, document a positive clinical response to Radicava ORS therapy.
    SourceLink
    On This Page
    Coverage CriteriaAuthorization and Documentation RequirementsTherapy OverviewInitial TherapyReauthorization